Abstract: Compositions and methods for assessing inflammation in a subject. The present disclosure provides compositions for labeling leukocytes with a 19F-containing perfluoropolyether molecule ex vivo. In some examples, the leukocytes are obtained from the patient, enriched in a whole blood fraction, and then labeled. The labeled cells may be re-introduced into the patient. The leukocytes may accumulate at a site of inflammation, thus permitting non-invasive evaluation of inflammation in patients. The present methods provide a tool for assessing inflammation in a wide variety of autoimmune diseases and may have particular utility in intestinal diseases such as Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cardio myositis.
Type:
Application
Filed:
August 26, 2014
Publication date:
October 13, 2016
Applicant:
Celsense, Inc.
Inventors:
Brooke M. Helfer, Anthony G. Balducci, Charles F. O'Hanlon, III
Abstract: Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19F-containing perfluoropolyether molecule ex vivo. In some examples, the leukocytes are obtained from the patient, enriched in a whole blood fraction, and then labeled. The labeled cells may be re-introduced into the patient. The leukocytes may accumulate at a site of inflammation, thus permitting non-invasive evaluation of inflammation in patients. The present methods provide a tool for assessing inflammation in a wide variety of autoimmune diseases and may have particular utility in intestinal diseases such as Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cardio myositis.
Type:
Application
Filed:
February 12, 2016
Publication date:
August 18, 2016
Applicant:
Celsense, Inc.
Inventors:
Brooke M. Helfer, Anthony G. Balducci, Charles F. O'Hanlon, III
Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substitute.
Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell members, in vivo. In certain embodiments, emulsions can be used as an artificial blood substrate.
Abstract: The disclosure provides, in part, compositions and methods for producing emulsions. In certain embodiments, emulsions of the disclosure can be used for the detection of inflammation and cell tracking using MRI. The disclosure provides, in part, methods for labeling, detecting and quantifying cell numbers in vivo.
Abstract: The disclosure relates to methods for labeling cells ex vivo with agents that can be detected by MRI or PET techniques, or other techniques that permit non-invasive imaging of living organisms. The labeled cells can be re-administered to the patient and the movements of the labeled cells can be tracked in vivo by MRI, PET or other techniques. In part, the disclosed methods involve labeling a series of cell samples ex vivo determining the association of label with the cells, such that an appropriate dosage of labeled cells can be determined for each patient.